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Introduction
Hodgkin’s lymphoma (HL) is one of the most common
malignancies in young adults.1,2 The cure rate of patients with
early stage disease is high when treated with two to six cycles
of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
chemotherapy followed by involved field radiotherapy.3-5
While consolidation radiotherapy is part of treatment for
patients with early stage Hodgkin’s lymphoma in the ESMO
clinical recommendations,6 the NCCN guidelines7 consider
chemotherapy alone an alternative treatment option. 
Depending on intensity and dose of treatment, long-term
complications such as secondary malignancies,8 cardiac disease9
and infertility10 are common in Hodgkin’s survivors. For
patients with early stage disease, the 20-year cumulative sec-
ondary malignancy rate is estimated between 4% and 20%.8,11
Risk factors for secondary malignancies and cardiac disease are
the choice and dose of chemotherapy and radiotherapy.8,11-17
Unfortunately, long-term comparisons of combined modality
treatment with chemotherapy alone (CT-alone) are difficult
in cohorts of Hodgkin’s survivors. Nonetheless, to avoid addi-
tional radiation-induced toxicity, chemotherapy-only treat-
ment for patients with early stage HL has been advocated.18,19
This notion was supported by two clinical trials comparing
CMT with chemotherapy alone in which no significant sur-
vival disadvantage was observed in patients receiving
chemotherapy alone.20,21 In both trials, 5-year progression-free
survival was better in the group receiving consolidation radio-
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therapy. 
The main objective of this systematic review was to
compare chemotherapy alone with identical chemothera-
py plus radiotherapy in patients with early stage HL with
respect to overall survival, tumor control and complete
response rates. 
Design and Methods 
Search methods and literature search 
A protocol with a detailed analysis plan was published in the
Cochrane Library.20 We searched the Cochrane Central Register of
Controlled Trials, MEDLINE and EMBASE from January 1980 to
February 2009. Proceedings of the American Society of
Hematology and abstracts of the American Society of Clinical
Oncology were hand-searched for the years 1980 to 2008.
Proceedings of the International Symposium on Hodgkin
Lymphoma were searched from 2004 on. No language restriction
was applied.
Randomized controlled trials comparing chemotherapy alone
with identical chemotherapy regimens combined with radiother-
apy in newly diagnosed HL patients of all ages in clinical stage
(CS) I and CS II were included. Trials with less than 80% of
patients in CS I or II were excluded according to our review pro-
tocol22 but included in sensitivity analysis. Similarly, trials where
the number of cycles varied between treatment arms were only
included in sensitivity analyses. Two reviewers screened the
abstracts retrieved. Duplicate reports were identified. All included
trials were assessed for quality parameters such as randomization,
concealment of allocation, masking of patients, care givers and
outcome assessors, similarity of baseline patients’ characteristics,
documentation of dropouts, withdrawals and intention-to-treat
analysis. Data on patients’ baseline characteristics, chemotherapy
regimens, radiation procedures, outcomes, and definitions were
extracted independently by two reviewers. Discrepancies were
solved through a third reviewer. We contacted authors of the
respective publications to obtain missing information. 
Statistical methods
Treatment effect measures for complete remission (CR) were
calculated as relative risks. Treatment effect measures for time to
event data (OS, tumor control) of each trial were estimated as haz-
ard ratios, using methods described by Tierney and colleagues.23
Meta-analysis was performed using the fixed effects model. For
analyses with unexplained statistical heterogeneity (I2 statistics
value of 50% or more), a random effects model was used. A linear
regression test24 for small trial bias was not performed as the num-
ber of included trials was less than ten.25 Subgroup analysis with
respect to different chemotherapy regimens (CVPP, EBVP, ABVD),
radiation fields (extended field or involved field), different
sequences of chemotherapy and radiotherapy, bulky disease, early
favorable or early unfavorable disease were performed. Sensitivity
analyses included quality aspects that differed among trials and
included intention-to-treat analysis, drop-outs, allocation conceal-
ment, length of follow-up and date of recruitment, as well as the
effect of single large trials on overall result. In addition, trials that
did not fulfill the inclusion criteria of our review protocol, i.e. the
number of chemotherapy cycles varied between treatment arms
or too many patients in advanced stages, were included in sensi-
tivity analyses. If possible, subgroup information for patients with
early stages was used. Tests for interaction between subgroups
were performed. Analyses were performed using Review
Manager, version 5. Number needed to treat were calculated for
time to event outcomes as described by Altman and colleagues.26
Results of the literature search
we screened 2,742 abstracts and 51 relevant publications were
retrieved as full text. Of these, 41 were excluded (Figure 1) and
finally five trials21,27-30 with 1,245 patients from 10 publications
were included in the main analysis. All publications except for the
EORTC-GELA H9-F trial29 with three abstract publications5,29,31
and two presentations32,33 were full text publications. 
Among the excluded trials (according to our review protocol) a
number of trials were included in sensitivity analyses post hoc, as
they yielded relevant information to the underlying clinical ques-
tion. Three trials (566 patients) included patients of all stages and
reported some subgroup information for early stage patients.34-36
One of these trials examined patients with bulky disease and
residual masses after VEBEP chemotherapy (etoposide, epirubicin,
bleomycin, cyclophosphamide, prednisone) who were PET nega-
tive.36 One trial included patients in stages I through IIIa.37 Finally,
two trials were identified in which the patients in the chemother-
apy alone group received more cycles of chemotherapy than the
patients in the chemotherapy plus radiotherapy group.20,38
Characteristics and main results of these trials are described in the
Online Supplementary Table S1. 
For certain risk factors, such as bulky disease, definitions varied
between trials (Table 1). Inclusion criteria regarding risk factors also
differed. While three trials in the main analysis included both
patients with early favorable and early unfavorable stages,21,28,30 the
EORTC H9-F trial29 included only patients with early favorable dis-
ease. In contrast, the Mexico B2H031 trial27 had only patients with
bulky disease. Similar differences were observed in the trials includ-
ed only in sensitivity analysis (Table 1 and Online Supplementary
Table S1).
Most patients included in the main analyses were treated with
either ABVD chemotherapy (353/1,245)21,27 or EBVP (epirubicin,
bleomycin, vinblastine, prednisone)29 (578/1,245). Two older trials
used CVPP (cyclophosphamide, vinblastine, procarbazine, pred-
nisone).28,30 Recruitment ranged from the 1970s28 to 2004,29 and
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Figure 1. QUORUM diagram.
2692 publications excluded
2743 potentially relevant publications
identified and screened through the
electronic database searches
51 publications retrieved for more
detailed evaluation
5 included RCTs in 10 publications
(1245 patients)
41 publications excluded:
130 non-randomized comparisons or reviews
17 not CT versus CT+RT
1 not Hodgkin’s lymphoma
1 only advanced stages
4 < 80% early stage patients
(included in sensitivity analyses)
3 chemotherapy regimen differed
2 no relevant outcomes (patients presumably
included in an included trial)
median follow-up was two to 12 years. Four trials randomized
patients at diagnosis, while the EORTC-GELA H9-F trial29 ran-
domized patients after achieving CR after chemotherapy. 
Among the trials included only in sensitivity analyses,
chemotherapies used were ABVD,20,35 COPP/ABV,34 VEBEP,36
MOPP (mechlorethamine, vincristine, procarbazine, prednisone)37
and MOPP/ABVD.38
The quality of the trials in the main analysis was acceptable.
Randomization procedures were not reported in four of the five
trials;27-30 the randomization procedure was adequate in the
MSCKK trial #90-44.21 An intention-to-treat analysis was per-
formed in two trials.21,29 Only one trial had more than 10% drop-
outs or non-evaluable patients28 (Table 1). None of the trials
reported blinding of the assessor. The quality of the additional tri-
als for the sensitivity analyses was similar. 
Complete response rate
Four trials including 653 patients reported the CR rate and were
meta-analyzed.21,27,29,30 The relative risk of reaching CR was 1.07
(95% confidence interval (CI) =0.98 to 1.17). Due to the small
number of trials, subgroup and sensitivity analyses were not per-
formed. 
Tumor control
In the main analysis, four trials reported endpoints for tumor
control, such as event-free survival, time to treatment failure, pro-
C. Herbst et al.
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Table 1. Characteristics of included trials.
Trial Inclusion criteria Number of Treatment Median ITT- Not evaluated
patients follow-up analysis (%)
in years (range)
Mexico B2H03127 CS I – II 99 6xABVD 11.4 No 6
Supra-diaphragmatic disease (6.3-16.5)
Bulky disease 102 6xABVD+MF-RT
CALGB 7751 “poor prognosis” 18 6xCVPP 2 No 32
Interim results28 PS I – II (0 - not reported)
19 6xCVPP+IF-RT
EORTC-GELA H9-F CS I – II 130
Interim results29 Supra-diaphragmatic disease
All of the favorable features: 6xEBVP 4.3 Yes 0
(age <50 years, ESR <50 mm/h or B symptoms 6xEBVP+36 Gy (1.2-6.8)
and ESR <30 mm/h, 448 IF RT or 20 Gy IF-RT
mediastinal-thoracic ratio <0-35)
CR or CR (unconfirmed) after 6 cycles EBVP
GATLA 9-H-7730 CS I – II 142 6xCVPP 4 No 6
173 patients with favorable and 104 patients (not reported)
with unfavorable characteristics 
(age >45, sites >2, bulky tumor) 135 6xCVPP+IF-RT
MSCKK trial #90-4421 CS I – IIIA without bulky disease, 76 6xABVD 5.6 Yes 0 (OS)
#90-4421 13% with CS IIIA (0.1-10.4) (OS) 9 (CR, 
~ 30 to 50% unfavorable disease 76 6xABVD + IF-RT or EF-RT tumor control)
*CS: clinical stage; PS: pathological stage; NR: not reported; CVPP: cyclophosphamide, vinblastine, procarbazine, prednisone; ABVD: adriamycin, bleomycin, vinblastine, dacar-
bazine; EBVP: epirubicin, bleomycin, vinblastine, prednisone; IF-RT: involved-field radiotherapy; EF-RT: extended-field radiotherapy; MF-RT: mantle-field radiotherapy; SN-RT: subto-
tal-nodal radiotherapy; CT: chemotherapy; ITT: intention-to-treat; CR: complete response rate; OS: overall survival.
Figure 2. Meta-analysis of tumor control among patients with early stage Hodgkin’s lymphoma who received chemotherapy (CT) alone or
chemotherapy and radiotherapy (CMT). Solid squares represent effect estimates for the single trials, the size of square represents the weight
of individual studies in the meta-analysis. Horizontal lines indicate 95% confidence intervals (CIs). The width of diamonds shows the 95%
confidence intervals for the pooled hazard ratios. 
Hazard Ratio Hazard Ratio
Study Weight Random, 95% CI Random, 95% CI
EORTC-GELA H9-F 27.6% 0.27 [0.17, 0.43]
GATLA 9-H-77 28.2% 0.55 [0.35, 0.86]
Mexico B2H031 26.4% 0.29 [0.17, 0.48]
MSKCC trial #90-44 17.8% 0.85 [0.37, 1.94]
Total (95% CI) 100.0% 0.41 [0.25, 0.66]
Heterogeneity: Tau2=0.16; Chi2=9.47, df=3 (P=0.02); I2=68%
Test for overall effect: Z=3.64 (P=0.0003)
0.1 0.2 0.5 1 2 5 10
Favors CMT Favors CT-alone
gression-free survival, and time to progression. Exact definitions
are given in Table 2. The combination of chemotherapy and radio-
therapy improved tumor control with a hazard ratio (HR) of 0.41
(95% CI 0.25 to 0.66, random effects model; Figure 2). There was
clear statistical heterogeneity between trials (I2=68%) which may
in part be due to the different definitions used. For example, some
trials examined progression or treatment failure in all randomized
patients, while others examined disease free survival which is
restricted to patients who reached CR. A subgroup analysis by the
type of tumor control definition was statistically significant
(P=0.01), indicating that the variation in definitions for tumor con-
trol may be responsible for the observed heterogeneity. Other sub-
group and sensitivity analyses (see Design and Methods section)
showed neither statistically significant difference between sub-
groups nor resulted in a relevant reduction of statistical hetero-
geneity. 
All of the trials that did not meet the strict inclusion criteria of
our review protocol had an effect estimate in favor of combined
modality treatment.20,34-38 When including all of these trials into a
meta-analysis for tumor control, the HR was 0.38 (95% CI 0.28 to
0.51). When restricting the analysis to the trials that kept the num-
ber of cycles the same between the group that received radiother-
apy and those that did not34-37 the HR was 0.39 (95% CI 0.27 to
0.55).
Overall survival 
All five trials in the main analysis (1,245 patients) reported OS.
The addition of radiotherapy significantly improved OS
(HR=0.40; 95% CI 0.27 to 0.59) with small heterogeneity between
trials (I2=3%) (Figure 3). In three trials the hazard ratios were
extracted from survival curves or reported dates of deaths27,29,37
assuming constant censoring.23 While this assumption is problem-
atic for the EORTC-GELA H9-F trial29 because the no-radiation
arm was closed early, different estimates of censoring had little
effect on the estimated hazard ratio of the trial. Another uncertain-
ty in the hazard ratio calculation arose from a P value with only
one significant digit.30 The results of the meta-analysis were dom-
inated by the Mexico B2H031 trial,27 which had a weight of 50.4%
(Figure 3). When excluding the Mexico B2H031 trial27 from the
meta-analysis in a sensitivity analysis, the summary hazard ratio
remained statistically significant favoring CMT (0.57; 95% CI 0.33
to 0.98, I2=0%). None of the subgroup analyses showed statistical-
ly significant differences between the subgroups examined (type
of chemotherapy, early favorable or unfavorable disease, bulky or
no bulky disease, type and timing of radiation therapy, quality
measures). 
The sensitivity analysis that included trials not fulfilling the
inclusion criteria of our review protocol20,34-38 yields a HR of 0.60
(95% CI 0.35 to 1.03), I2=48%. When excluding the trials where
the number of cycles varies, the HR was 0.46 (95% CI 0.27 to
0.78), I2=27% with the remaining heterogeneity due to the
O’Dwyer trial. The two trials that examined chemotherapy plus
radiotherapy versus more chemotherapy reported conflicting
results among the two trials.20,38 The trial by Meyer and col-
leagues20 comparing four cycles of ABVD plus subtotal nodal irra-
diation with six cycles of ABVD had an (estimated) HR of 1.73
Combined modality treatment (CMT)
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Table 2. Definitions of tumor control.
Trial Definition of tumor control
Mexico B2H031 Contradictory definitions. In the Design and Methods section: “Disease free survival was calculated for CR patients from the
beginning of treatment until clinically or radiologically and biopsy proven relapse.” In the Results section percentages 
of disease free survival were calculated based on the full population. 
EORTC-GELA Definition of disease free survival not reported. Note: all patients are in CR at the time of randomization.
H9-F
GATLA 9-H-77 Patients who failed to respond were evaluated as relapsed at first month. Patients in CR were evaluated from date of CR
to date of first relapse or death.
MSCKK trial #90-44 Time from enrolment until any progression of disease. 
Figure 3. Meta-analysis of OS among patients with early stage Hodgkin’s lymphoma, who received chemotherapy (CT) alone or chemother-
apy and radiotherapy (CMT). Solid squares represent effect estimates for the single trials, the size of square represents the weight of indi-
vidual studies in the meta-analysis. Horizontal lines indicate 95% confidence intervals (CIs). The width of diamonds shows the 95% confi-
dence intervals for the pooled hazard ratios. 
0.05 0.2 1 5 20
Favor CMT Favors CT-alone
CALGB 7751 5.1% 0.63 [0.11, 3.65]
AORTC-GELA H9-F 4.6% 0.27 [0.04, 1.74]
GATLA 9-H-77 30.7% 0.68 [0.33, 1.40]
Mexico B2H031 50.4% 0.29 [0.17, 0.51]
MSKCC trial #90-44 9.2% 0.31 [0.08, 1.14]
Total (95% CI) 100.0% 0.40 [0.27, 0.59]
Heterogeneity: Tau2=0.00; Chi2=3.89, df=4 (P=0.42); I2=0%
Test for overall effect: Z=4.57 (P<0.00001)
(95% CI 0.62 to 4.86), while the Kung trial38 comparing four cycles
of MOPP/ABVD + IF-RT with six cycles of MOPP/ABVD had an
estimated HR of 0.86 (95% CI 0.29 to 2.54). 
Discussion 
The following findings emerge from this meta-analysis:
(i) In patients with early stage HL, there is no evidence
that the complete response rate is different in patients
receiving chemotherapy alone compared to those receiv-
ing CMT; (ii) tumor control is better in patients receiving
CMT compared to chemotherapy-alone (HR 0.41; 95% CI
0.25 to 0.66). The median observation in this meta-analy-
sis is approximately five years, and (iii) adding radiothera-
py to chemotherapy improves the OS in this group of
patients (HR 0.40; 95% CI 0.27 to 0.59). 
To our knowledge, this is the first comprehensive
review focusing on patients with early stage Hodgkin’s
lymphoma that compares chemotherapy alone with CMT
consisting of chemotherapy plus additional radiotherapy.
The main analysis according to the strict inclusion criteria
of our review protocol included five randomized con-
trolled trials with 1,245 patients of both early favorable
and early unfavorable Hodgkin’s lymphoma. The litera-
ture search revealed a number of trials with more than
20% of patients in advanced stages or with fewer cycles
of chemotherapy in patients receiving radiotherapy.
Because these trials were considered to be relevant to the
underlying clinical question, these trials were included in
sensitivity analyses, where subgroup information of early
stage patients was used if available. These sensitivity
analyses underlined the results of the main analyses. 
The effect estimate for tumor control is high with an HR
of 0.41 (0.25 to 0.66). This corresponds to 6 patients (95%
CI 5 to 11) requiring treatment with CMT to prevent one
additional relapse, progression or death in the chemother-
apy alone group, assuming a 5-year tumor control of 70%
in the CT-alone group. Unfortunately, the meta-analysis
had substantial heterogeneity, which may in part be due
to the variety of definitions used by the individual trials.
However, all trials (even those included only in sensitivity
analyses) had an effect estimate favoring CMT. This is not
surprising given that radiotherapy is a very effective treat-
ment for Hodgkin’s lymphoma. 
The hazard ratio for overall survival (0.40; 95% CI 0.27
to 0.59) is similar to that of tumor control. With an
assumed OS of 85% at five years as observed in three of
the trials included here,21,27,30 approximately 11 patients
(95% CI 9 to 18) would require treatment with CMT for
one additional patient to survive during the first five years.
With better survival (97·5%) as reported in the EORTC-
GELA H9-F trial,29 approximately 55 patients (95% CI 46
to 86) would be needed. These potentially surprising
results were robust when excluding the Mexico B2H031
trial,27 which had a high weight in the analysis due to the
long follow-up and relatively high mortality. The only
concern in the overall survival analyses stem from hazard
ratios estimated from survival curves27-29 and the use of
preliminary data from the EORTC-GELA H9-F trial.29
However, these are minor points, as the direction of the
effect is clear and only the magnitude may vary slightly.
Again, the trials included in the sensitivity analyses20,34-38
also supported the results in favor of CMT. Three trials
had effect estimates favoring CMT, two trials observed no
deaths34,36 and only one trial20 observed a slight effect
favoring chemotherapy alone, which was not statistically
significant. The trial by Meyer and colleagues20 replaced
two to four cycles of ABVD chemotherapy with subtotal
nodal irradiation. It is, therefore, not directly comparable
to the trials which used the same number of cycles in both
arms of the trials, nor to trials examining smaller radiation
fields. The other trial with a similar trial design had an
effect favoring CMT.38
In the present analyses we found no evidence for inter-
action of treatment options or patients’ characteristics.
Two of the five trials of the main analysis employed
ABVD, and the summary hazard ratios in the subgroup
analyses by chemotherapy regimen were very similar. No
difference in tumor control or OS was observed between
trials that examined the addition of involved field or
extended field radiotherapy. This is in line with the find-
ing that extended field radiotherapy had little or no advan-
tage over involved field radiotherapy in Hodgkin’s
patients when used alone or after effective chemothera-
py.3,8 In addition, subgroup analyses gave no hint that the
hazard ratios may differ depending on the proportion of
patients with early favorable or early unfavorable disease
or the inclusion or exclusion of patients with bulky dis-
ease. However, due to the small number of trials included,
reliable information from subgroup analyses is unlikely.
Long-term adverse effects such as secondary malignan-
cies or cardiac disease are important in HL patients and
can occur later than the reported observation times of the
discussed trials. Radiotherapy can induce secondary
malignancies while the exact increase in the risk is unclear.
The absolute risk difference between chemotherapy alone
and chemotherapy plus radiotherapy in a recent individual
patient data meta-analysis was about 1% in early stage
patients at 15 years.8 Cohorts of Hodgkin’s patients of any
stage suggest that this difference is much higher.8,11-17,39
However, patients who relapse have a more pronounced
risk of secondary malignancies according to a cohort study
by Aleman and colleagues.16 Therefore, the addition of
radiotherapy which reduces the number of patients with
relapse (who require more aggressive therapy) may con-
tribute to a smaller overall risk difference than suggested
by the cohorts who do not distinguish between relapsed
and non-relapsed patients when evaluating the risk of
radiotherapy. 
Cardiac disease is associated with mediastinal radiation
and with the cumulative dose of chemotherapy, in partic-
ular doxorubicin. Radiation fields have been reduced sub-
stantially from extended field radiotherapy to involved
field or even the involved node radiotherapy used today.
Replacing consolidation radiotherapy with chemotherapy,
as evaluated by Meyer and colleagues,20 increases the dose
of doxorubicin and may thus increase long-term cardiac
toxicity. Importantly, there was also a detrimental effect
on progression-free survival in the group of patients
receiving chemotherapy only. 
Identifying patients at low risk of relapse might be con-
sidered an alternative to consolidation radiotherapy for all
patients. Currently, however, no reliable evidence for such
a strategy exists. In this meta-analysis, the presence of
C. Herbst et al.
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conventional complete response after chemotherapy such
as ABVD21,27 or EBVP29 does not seem to accurately identi-
fy a group of patients who do not benefit from radiother-
apy with regard to tumor control. PET may be an alterna-
tive. However, in patients with bulky early stage disease
having residual masses in CT that are PET negative, the
rate of relapse after ABVD chemotherapy was much high-
er in patients who did not receive consolidation radiother-
apy.36 Two other trials are planned or underway in patients
with early stage Hodgkin’s lymphoma (clinicaltrials.gov
identifiers: NCT00736320, NCT00433433). 
In conclusion, additional radiotherapy prevents relapse
and improves 5-year overall survival in patients with early
stage Hodgkin’s lymphoma. Combined modality treat-
ment (ABVD and consolidation radiotherapy) is standard
of care in this patient group.
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